GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration

NCT02302976 · Completed

Last updated 2026-05-28

This clinical trial tests whether a medication that mimics a gut hormone can reduce the pleasurable effects of cocaine and cravings in adults with cocaine dependence.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind study

Participants 13 people

Who can join Ages 18–50 · all sexes

Timeline Started 2014-11 · est. completion 2018-08

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT02302976 ↗

Description as written by the study sponsor.

The investigators plan to explore the effects of acute pre-treatment with the glucagon like peptide-1 (GLP-1) agonist, exenatide versus placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. Additionally, the investigators plan to explore the effects of sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g., euphoric) and behavioral (self-administration) effects of cocaine in experienced, non-treatment seeking users of the drug.

Treatments tested

cocaine hydrochloride Drug
exenatide also known as byetta Drug
placebo Drug

Main thing measured	Mean cocaine inter-infusion interval
Sponsor	Yale University
Conditions studied	Cocaine Dependence
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02302976 ↗